Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | ALB | P02768 | 6/20 | 0.52 |
| ▸ | IL2 | P60568 | 6/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | DDO | Q99489 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249945 | 0.96 | FLT3 (0.55) | FLT3HRH4ALBIL2DAO | |
| SCHEMBL20535834 | 0.85 | FLT3 (0.50) | FLT3HRH4MAPTKIF11ALOX5 | |
| SCHEMBL28046328 | 0.84 | HRH4 (0.52) | FLT3HRH4ALBIL2DAO | |
| SCHEMBL5622391 | 0.84 | KDM4E (0.55) | FLT3HRH4ALBIL2DAO | |
| SCHEMBL30310659 | 0.83 | HRH4 (0.55) | FLT3HRH4MAPTKIF11CYP1A2 | |
| SCHEMBL2134591 | 0.83 | FLT3 (0.58) | FLT3DAODDOMAPTKIF11 | |
| SCHEMBL915460 | 0.83 | HRH4 (0.55) | FLT3HRH4MAPTKIF11CYP1A2 | |
| SCHEMBL16234660 | 0.82 | HRH4 (0.59) | FLT3HRH4ALBIL2DAO | |
| SCHEMBL3417091 | 0.82 | FLT3 (0.60) | FLT3HRH4ALBIL2DAO | |
| SCHEMBL30189206 | 0.82 | FLT3 (0.60) | FLT3HRH4ALBIL2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534151-B1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2018-11-14 | — | — | EP | disclosed |
| EP-2632261-B1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | disclosed |
| EP-1966134-B1 | NOVEL FUSED PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-8658794-B2 | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof | MERCK SHARP & DOHME B.V. (NL) | 2014-02-25 | — | — | US | disclosed |
| WO-2013163466-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-2635567-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2013-09-11 | — | — | EP | disclosed |
| EP-2632261-A1 | INHIBITORS OF HEPATITIS C VIRUS | Presidio Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | disclosed |
| EP-2534151-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MSD Oss B.V. (NL) | 2012-12-19 | — | — | EP | disclosed |
| US-6335360-B1 | INDOLINE-2-CARBOXYLIC AMIDE DERIVATIVES; OBESITY, EATING AND PSYCHOLOGICAL DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-01-01 | — | — | US | disclosed |
| CN-1067988-C | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 2001-07-04 | — | — | CN | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| CN-1051301-C | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 2000-04-12 | — | — | CN | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| CN-1136038-A | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 1996-11-20 | — | — | CN | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| CN-1106800-A | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 1995-08-16 | — | — | CN | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217702-A1 | INDOLE DERIVATIVES | BDKRB1, BDKRB2, ARRB1 | FLT3 2128/4885HRH4 18/4885ALB 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.